Rain Therapeutics

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.  Rain Oncology provides a tumor-agnostic strategy to select patients based on tumors’ underlying genetics rather than histology.  Rain Oncology was founded in 2017 and was headquartered in Newark, California.

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , July 3, 2023 /PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Rain and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00.

RAIN ALERT: The Law Offices of Vincent Wong Investigate Rain Oncology Inc. for Potential Violations of Securities Laws

NEW YORK , June 30, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/rain-class-action-loss-submission-form/?id=41539&from=4 Further details on the investigation: On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00. Then, on May 22, 2023, Rain issued a press release announcing topline results from its Phase 3 MANTRA trial of milademetan for the treatment of dedifferentiated liposarcoma ("DD LPS").

RAIN FRAUD ALERT: Jakubowitz Law is Investigating Rain Oncology Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 29, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) concerning possible violations of federal securities laws. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00.

RAIN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Rain Oncology Inc.

NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) violated federal securities laws. CURRENT INVESTIGATION DETAILS:On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00.

RAIN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Rain Oncology Inc.

LOS ANGELES, CA / ACCESSIWRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial –

Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $RAIN #RAIN--The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.

Why Shares of Rain Oncology Are Plummeting Today

Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 MANTRA trial failed to meet its primary endpoint.

Why Is RAIN Stock Down 87% Today?

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care –

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Finance Conference Call Participants Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Joe Catanzaro - Piper Sandler Soumit Roy - Jones Trading Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Faisal Khurshid - SVB Securities Mitchell Kapoor - H.C. Wainwright Avantika Joshi - Mizuho Securities Tony Butler - EF Hutton Operator Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call.

Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023

NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

Rain Oncology Inc. (NASDAQ:RAIN ) Q4 2022 Results Conference Call March 9, 2023 5:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele - Chief Scientific Officer Richard Bryce - Chief Medical Officer Nelson Cabatuan - Senior Vice President-Finance Conference Call Participants Michael Schmidt - Guggenheim Partners Joseph Catanzaro - Piper Sandler Soumit Roy - Jones Research Jeff Jones - Oppenheimer Yigal Nochomovitz - Citigroup Sam Slutsky - Lifesci Capital Graig Suvannavejh - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Tony Butler - EF Hutton Kumar Raja - Roth Capital Partners Operator Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call.

Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript

– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –

Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.

Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Citi Virtual Oncology Leadership Summit on Tuesday, February 21, 2023, at 12:00 p.m. ET, being held virtually.

News for Rain Therapeutics Stock (RAIN)